MenaQ7
Commercial- Indications
- Bone health, Cardiovascular health
Company intelligence / Profile preview
NattoPharma established the global market and scientific foundation for vitamin K2 as menaquinone‐7 (MK‐7), branded as MenaQ7®. Over twenty human clinical trials have demonstrated safety and efficacy in supporting bone and cardiovascular health. The company also developed a synthetic pharmaceutical-grade MK‐7 active pharmaceutical ingredient with documented purity, aiming at future drug development. Clinical research continues under the new parent company.
No approved drugs yet; commercialized globally as a supplement ingredient.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NattoPharma.